# Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine

> **NCT00128011** · PHASE2 · COMPLETED · sponsor: **International Vaccine Institute** · enrollment: 150 (—)

## Conditions studied

- Cholera

## Interventions

- **BIOLOGICAL:** killed oral cholera vaccine

## Key facts

- **NCT ID:** NCT00128011
- **Lead sponsor:** International Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 150 (—)
- **Last updated:** 2006-11-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128011, "Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00128011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*